
IQVIA
IQV · NYSE · Life Sciences Tools & Services
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $43,2 bn
- Div. yield
- —
- Year to date
- +17,6%
Ratio score
based on 9 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
5 ✓ · 3 — · 1 ✕ · 1 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 31,3 | 30,9 | 37,9 |
| Forward P/E | 20,2 | — | 29,5 |
| PEG | 2,5 | — | 3,7 |
| P/S | 2,5 | 2,5 | 6,6 |
| EV/EBITDA | 16,8 | 16,3 | 29,9 |
| P/FCF | 21,0 | — | 38,7 |
| P/B | 6,6 | 6,2 | 5,4 |
Industry median — across 11 profitable companies in “Life Sciences Tools & Services” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 26 analysts
- Buy
- 24
- Hold
- 2
- Sell
- 0
Beat the EPS forecast in 3 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q3 2026 | 3,31 | 3,34 | Up +0,9% |
| Q2 2026 | 3,06 | 3,15 | Up +2,9% |
| Q1 2026 | 2,85 | 2,90 | Up +1,9% |
| Q4 2025 | 3,43 | 3,42 | Down −0,3% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,43 bn | 4,37 bn | 4,15 bn | 4,36 bn | 4,10 bn | 4,02 bn | 3,83 bn | 3,96 bn | 3,90 bn | 3,81 bn | 3,74 bn | 3,87 bn |
| EPS | 2,10 | 1,53 | 1,61 | 2,98 | 1,93 | 1,54 | 1,40 | 2,41 | 1,55 | 1,97 | 1,56 | 2,53 |
| Margin | 7,9% | 5,9% | 6,6% | 11,8% | 8,1% | 6,6% | 6,5% | 11,0% | 7,3% | 9,5% | 7,7% | 12,1% |
| FCF | 667 m | 360 m | 491 m | 561 m | 772 m | 292 m | 426 m | 721 m | 571 m | 445 m | 377 m | 568 m |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: no purchases, sales $39,3 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| sherbet eric9 Nov 2026 · sale | $1,24 m | 4 446 | $278,83 |
| berkshire james g.2 Sep 2026 · sale | $697 228 | 2 668 | $261,33 |
| staub w richard3 Aug 2026 · sale | $1,28 m | 5 500 | $232,68 |
| patel bhavik31 Jul 2026 · sale | $436 426 | 1 855 | $235,27 |
| sherbet eric29 Jul 2026 · sale | $1,25 m | 5 000 | $249,16 |
| cherofsky keriann29 Jul 2026 · sale | $136 827 | 558 | $245,21 |
| bousbib ari29 Jul 2026 · sale | $13,0 m | 53 191 | $244,78 |
| bousbib ari29 Jul 2026 · sale | $10,8 m | 44 039 | $246,08 |
| bousbib ari29 Jul 2026 · sale | $1,13 m | 4 584 | $246,85 |
| bousbib ari29 Jul 2026 · sale | $1,10 m | 4 465 | $247,10 |
| bousbib ari18 Dec 2025 · sale | $8,13 m | 36 564 | $222,43 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Life Sciences Tools & Services
- Exchange
- NYSE
- Country
- US
- IPO date
- 9 May 2013
- Website
- ir.iqvia.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
WATWaters Corporation | $453,42 | 29★★★★★★★would not consider | 269,0 | — | 1,8% |
AAgilent Technologies | $172,92 | 78★★★★★★★★★would consider | 34,1 | +8,6% | 19,5% |
MTDMettler Toledo | $1 727,26 | 63★★★★★★★★would watch | 36,5 | +6,5% | 22,2% |
ILMNIllumina, Inc. | $198,00 | 75★★★★★★★★★would consider | 33,6 | +5,8% | 19,7% |
WSTWest Pharmaceutical Services | $417,80 | 83★★★★★★★★★would consider | 45,5 | +12,6% | 18,8% |
Ratio — a score by our methodology, not an investment recommendation.




